RCL

Part of a nucleotide salvage pathway that eliminates epigenetically modified 5-hydroxymethyl-dCMP (hmdCMP) in a two-step process entailing deamination to cytotoxic 5-hydroxymethyl-dUMP (hmdUMP), followed by its hydrolysis into 5-hydroxymethyluracil (hmU) and 2-deoxy-D-ribose 5-phosphate (deoxyribosephosphate) (PubMed:33833118). Catalyzes the second step in that pathway, the hydrolysis of the N-glycosidic bond in hmdUMP, degrading this cytotoxic nucleotide to avoid its genomic integration (PubMed:33833118).

Belongs to the 2'-deoxynucleoside 5'-phosphate N-hydrolase 1 family.

Expressed at low levels in brain, colon, lung, peripheral blood leukocytes, placenta, small intestine, and thymus. Expressed at high levels in heart, kidney, liver, skeletal muscle and spleen. Overexpressed in a significant proportion of breast cancers.

• Cytoplasm
• Nucleus

C6orf108, RCL, DNPH1, 5-hydroxymethyl-dUMP N-hydrolase, 2'-deoxynucleoside 5'-phosphate N-hydrolase 1, c-Myc-responsive protein RCL

• entrezGene:10591
• swissprot:O43598

Proteins

Oncology

19108Da